- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05110014
Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety
Substudy of Protocol NCT03843957: Effect of mPATH on Screening for Depression, Fall Risk, and Safety
Study Overview
Detailed Description
As part of the parent study (NCT0343957), investigators developed an iPad program called mPATH that patients use at their primary care clinician's office to encourage colorectal cancer screening. To encourage practices to use mPATH with every patient, the investigators included in the program the health system's required screening items for depression, fall risk, and intimate partner violence, thereby offloading this routine task from clinical staff. It is possible that mPATH will increase detection of depression, fall risk, and intimate partner violence because: 1) mPATH systematically asks these screening items of all patients, and 2) patients may feel more comfortable answering these items on an iPad survey than during an in-person interview.
To determine the effect of mPATH on the performance of this screening, investigators will examine a limited use dataset comparing the 2 months before a clinic started using mPATH to the 2 months after the clinic began using mPATH. Because clinics may need some time to fully adopt mPATH, investigators will exclude the first two weeks following the launch of mPATH.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 or older
- Completed a provider visit at the study clinic during the 60 days prior to the clinic launching the mPATH program (the "pre" time period), or completed a provider visit at the study clinic during days 14 - 73 after the launch of mPATH (the "post" time period)
- Have a preferred language of English or Spanish
Exclusion Criteria:
• Requiring a language interpreter for a language other than Spanish
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Primary Care Office Visits
The limited use dataset will contain the following data elements for each completed patient visit:
|
mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Screening Positive for Depression, Fall Risk or Intimate Partner Violence - Pre mPATH Use
Time Frame: 2 months prior to use of intervention
|
The primary outcome will be the proportion of patients seen in each time period ("pre" vs. "post") who screen positive for depression, fall risk, or intimate partner violence.
The "pre" time period will be Days -60 to -1 (the 60 day period before mPATH Launch).
Screening positive for depression will be a score of 3 or greater on the Patient Health Questionnaire-2.
Screening positive for fall risk will be answering "yes" to having a device to assist with mobility and/or having fallen in the last year.
Screening positive for intimate partner violence will be answering yes to any of the health system's three questions about safety in the home.
|
2 months prior to use of intervention
|
Number of Participants Screening Positive for Depression, Fall Risk or Intimate Partner Violence - Post mPATH Use
Time Frame: 2 months after use of intervention
|
The primary outcome will be the proportion of patients seen in each time period ("pre" vs. "post") who screen positive for depression, fall risk, or intimate partner violence.
The "post" time period will be days 14 to 73 (the 60 day period commencing 2 weeks after mPATH Launch).
Screening positive for depression will be a score of 3 or greater on the Patient Health Questionnaire-2.
Screening positive for fall risk will be answering "yes" to having a device to assist with mobility and/or having fallen in the last year.
Screening positive for intimate partner violence will be answering yes to any of the health system's three questions about safety in the home.
|
2 months after use of intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Screening Positive for Depression Using Patient Health Questionnaires (PHQ-2 Score of 3 or Greater)
Time Frame: 2 months before and 2 months after using intervention
|
The PHQ-2 inquires about the frequency of depressed mood and anhedonia over the past two weeks.
Screen positive for depression using the PHQ-2 items.
PHQ-2 score obtained by adding score for each question (total points).
A PHQ-2 score ranges from 0-6.
If the score is 3 or greater, major depressive disorder is likely.
|
2 months before and 2 months after using intervention
|
Number of Participants Screening Positive for Moderately Severe or Severe Depression Using Patient Health Questionnaires (PHQ-9 Score Greater Than 14)
Time Frame: 2 months before and 2 months after using intervention
|
The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
PHQ-9 score obtained by adding score for each question (total points).
Total scores of 5, 10, 15, and 20 represent cut points for mild, moderate, moderately severe and severe depression, respectively.
|
2 months before and 2 months after using intervention
|
Number of Participants Screening Positive for Severe Depression Using Patient Health Questionnaires (PHQ-9 Score Greater Than 19)
Time Frame: 2 months before and 2 months after using intervention
|
The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
PHQ-9 score obtained by adding score for each question (total points).
Total scores of 5, 10, 15, and 20 represent cut points for mild, moderate, moderately severe and severe depression, respectively.
|
2 months before and 2 months after using intervention
|
Number of Participants With a Patient Health Questionnaires (PHQ-9 Score Greater Than 14) and Not Currently Taking a Medication for Depression.
Time Frame: 2 months before and 2 months after using intervention
|
The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
PHQ-9 score obtained by adding score for each question (total points).
Total scores of 5, 10, 15, and 20 represent cut points for mild, moderate, moderately severe and severe depression, respectively.
|
2 months before and 2 months after using intervention
|
Number of Participants Who Report Thoughts of Self Harm - Patient Health Questionnaire (PHQ-9) in All Practices
Time Frame: 2 months before and 2 months after using intervention
|
This is measured by the screening question on suicide risk on the PHQ-9: "Thoughts that you would be better off dead or of hurting yourself in some way."
|
2 months before and 2 months after using intervention
|
Number of Participants Screening Positive for Fall Risk at Home in All Practices
Time Frame: 2 months before and 2 months after using intervention
|
Screen positive for fall risk at home. In addition, the outcomes below will be assessed:
|
2 months before and 2 months after using intervention
|
Number of Participants Screening Positive for Intimate Partner Violence in All Practices
Time Frame: 2 months before and 2 months after using intervention
|
Screen positive for safety concerns at home. In addition, the outcome below will be assessed:
|
2 months before and 2 months after using intervention
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: David Miller, MD, MS, Wake Forest Baptist Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00048919.sub
- R01CA218416 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on Primary Care Office Visits
-
Kaiser PermanenteCompletedObesity | OverweightUnited States
-
George Washington UniversityYouBelong Uganda; Butabika National Referral HospitalRecruiting
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart FailureUnited States
-
University of Wisconsin, MadisonStanford UniversityCompleted
-
Boston Medical CenterNational Institute of Mental Health (NIMH)Active, not recruiting
-
Carlos III Health InstituteHealth Department of the Basque GovernmentCompleted
-
University of VirginiaRecruitingMyelodysplastic Syndromes | AML, Adult | ALL, Adult | Leukemia, AcuteUnited States
-
Medtronic Cardiac Rhythm and Heart FailureSymbios ClinicalCompletedAtrial Fibrillation | Arrhythmia | Ventricular Fibrillation | TachycardiaUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)Not yet recruitingSubstance UseUnited States
-
University of California, DavisCompleted